Novartis And Idenix Seek European Approval Of Telbivudine (LDT600) For The Treatment Of Patients With Chronic Hepatitis Medical News Today - Feb 12 8:09 PM
Novartis and Idenix Pharmaceuticals, Inc. announced today the European submission of telbivudine (LTD600) for approval as a novel treatment for patients affected by chronic hepatitis B (CHB), a potentially fatal disease estimated to affect more than three million people in Europe1 and over 350 million people worldwide... click link for more info.Save to My Web
Peregrine Announces Completion of Planned Patient Enrollment and Dosing in Initial Tarvacin(TM) Anti-Viral Hepatitis C [Press Release] PR Newswire via Yahoo! Finance - Feb 15 4:00 AM
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has completed planned patient enrollment and dosing in its initial Phase l clinical trial for Tarvacin Anti-Viral in the treatment of chronic hepatitis C virus infection .Save to My Web
XTL Biopharmaceuticals to Present at the JPMorgan Small Cap Conference [Press Release] PR Newswire via Yahoo! Finance - Feb 13 12:05 AM
XTL Biopharmaceuticals, Ltd. , a biopharmaceutical company developing drugs against hepatitis, announced today that Ron Bentsur, Chief Executive Officer, will present an overview of the Company at The JPMorgan Small Cap Conference in Philadelphia.Save to My Web
Schering-Plough Drug Gets Fast Track AP via Yahoo! Finance - Jan 30 6:44 AM
Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment.Save to My Web
Peregrine Pharmaceutical Will Deliver Hepatitus C Phase I Safety Data At 2nd Annual Viral And Hepatitus Drug And Medical News Today - Feb 23 3:11 AM
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has completed planned patient enrollment and dosing in its initial Phase l clinical trial for Tarvacin(TM) Anti-Viral in the treatment of chronic hepatitis C virus infection (HCV)... click link for more Save to My Web